| Name | Title | Contact Details |
|---|
Quality Turf Farms is a West Columbia, TX-based company in the Business Services sector.
Convergent Energy and Power is a prominent independent developer of energy storage solutions in North America, with over a decade of experience in financing, developing, commissioning, and operating energy storage assets. The company focuses on providing cost-effective solutions that integrate renewable energy sources and enhance grid resilience. Convergent specializes in energy storage systems that store electricity during surplus periods and dispatch it back to the grid when needed. They also offer solar-plus-storage systems, combining solar power with energy storage for a comprehensive renewable energy approach. Their proprietary PEAK IQ® Energy Storage Intelligence platform optimizes asset performance, helping customers save on electricity bills and defer infrastructure upgrades. The company serves a diverse clientele, including large industrial customers, electric cooperatives, municipal utilities, investor-owned utilities, and Fortune 100 businesses. With over $1 billion committed to energy storage and solar-plus-storage systems, Convergent is well-equipped to support the transition to clean energy.
Cepemar Environmental Services is a Boca Raton, FL-based company in the Business Services sector.
IDAC WEST is a Vista, CA-based company in the Business Services sector.
Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.